Skip to content

Study · Randomized controlled trial · n = 10 · 1999

10 results

Effect of doses of glucagon used to treat food impaction on esophageal motor function of normal subjects.

Colon V, Grade A, Pulliam G, Johnson C, Fass R

Dysphagia1 Jan 1999Cited by 30 (Europe PMC)

PMID9828271 (opens in a new tab)DOI10.1007/pl00009581 (opens in a new tab)PepBankPUB-09828271
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In normal subjects, distal esophageal contraction amplitude decreased with increasing glucagon doses without statistical significance.

    In plain wordsIn normal subjects, higher glucagon doses reduced lower esophageal contraction strength, but the decrease was not statistically significant.

    Peptide
    Glucagon
    Outcome
    No significant changeDistal contraction amplitude
    Study

    n = 10

    Comparator
    Lower glucagon doses
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    0.25, 0.5, and 1 mg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Mean amplitude of contraction in the distal esophagus was further reduced with increased dosage of glucagon but did not achieve statistical significance.
    2 context sentences
    Summary · context
    We studied 10 normal subjects to determine the effect of doses of intravenous glucagon used to treat food impaction on esophageal motor function.
    Summary · context
    With a multilumen assembly perfused by a low compliance pneumohydraulic infusion pump, esophageal manometry was performed during baseline and after randomized administration of 0. 25, 0.5, and 1 mg intravenous glucagon.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In normal subjects, 0.5 mg glucagon further reduced LES resting pressure to 5.9 +/- 1.2 mmHg (p = 0.0009).

    In plain wordsIn normal subjects, 0.5 mg glucagon further reduced resting sphincter pressure compared with 0.25 mg.

    Peptide
    Glucagon
    Outcome
    DecreaseLES resting pressure after 0.5 mg
    Study

    n = 10

    Comparator
    0.25 mg glucagon
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    0.5 mg · intravenousAs given in this study (human).

    Measurements

    LES resting pressure (mean)
    5.9 mmHg
    after 0.5 mg glucagon
    LES resting pressure spread (+/-, as reported)
    1.2 mmHg
    after 0.5 mg glucagon

    Source sentences

    Summary
    Mean LES resting pressure was significantly reduced after 0.25 mg (18.7 +/- 1.8 vs. 10.2 +/- 1.5 mmHg, p = 0.0001) and further reduced after 0.5 mg (5.9 +/- 1.2 mmHg, p = 0.0009).
    2 context sentences
    Summary · context
    We studied 10 normal subjects to determine the effect of doses of intravenous glucagon used to treat food impaction on esophageal motor function.
    Summary · context
    With a multilumen assembly perfused by a low compliance pneumohydraulic infusion pump, esophageal manometry was performed during baseline and after randomized administration of 0. 25, 0.5, and 1 mg intravenous glucagon.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In normal subjects, 1 mg glucagon provided no further reduction in LES function parameters compared with 0.5 mg.

    In plain wordsIn normal subjects, 1 mg glucagon did not further reduce sphincter function measures compared with 0.5 mg.

    Peptide
    Glucagon
    Outcome
    No significant changeLES function parameters at 1 mg versus 0.5 mg
    Study

    n = 10

    Comparator
    0.5 mg glucagon
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    1 mg · intravenousAs given in this study (human).

    Source sentences

    Summary
    The 1-mg dose versus the 0.5-mg did not provide further reduction in any LES function parameters.
    2 context sentences
    Summary · context
    We studied 10 normal subjects to determine the effect of doses of intravenous glucagon used to treat food impaction on esophageal motor function.
    Summary · context
    With a multilumen assembly perfused by a low compliance pneumohydraulic infusion pump, esophageal manometry was performed during baseline and after randomized administration of 0. 25, 0.5, and 1 mg intravenous glucagon.
  4. 04HumanNon-randomized trialEfficacy outcome

    In normal subjects, glucagon did not affect proximal esophageal contraction amplitude.

    In plain wordsIn normal subjects, glucagon did not change upper esophageal contraction strength compared with baseline.

    Peptide
    Glucagon
    Outcome
    No significant changeProximal contraction amplitude
    Study

    n = 10

    Comparator
    Baseline
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    0.25, 0.5, and 1 mg · intravenousAs given in this study (human).

    Source sentences

    Summary
    No effect on proximal amplitude of contraction and proximal or distal esophageal contraction duration was noted.
    2 context sentences
    Summary · context
    We studied 10 normal subjects to determine the effect of doses of intravenous glucagon used to treat food impaction on esophageal motor function.
    Summary · context
    With a multilumen assembly perfused by a low compliance pneumohydraulic infusion pump, esophageal manometry was performed during baseline and after randomized administration of 0. 25, 0.5, and 1 mg intravenous glucagon.
  5. 05HumanNon-randomized trialEfficacy outcome

    In normal subjects, glucagon did not affect proximal esophageal contraction duration.

    In plain wordsIn normal subjects, glucagon did not change upper esophageal contraction duration compared with baseline.

    Peptide
    Glucagon
    Outcome
    No significant changeProximal contraction duration
    Study

    n = 10

    Comparator
    Baseline
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    0.25, 0.5, and 1 mg · intravenousAs given in this study (human).

    Source sentences

    Summary
    No effect on proximal amplitude of contraction and proximal or distal esophageal contraction duration was noted.
    2 context sentences
    Summary · context
    We studied 10 normal subjects to determine the effect of doses of intravenous glucagon used to treat food impaction on esophageal motor function.
    Summary · context
    With a multilumen assembly perfused by a low compliance pneumohydraulic infusion pump, esophageal manometry was performed during baseline and after randomized administration of 0. 25, 0.5, and 1 mg intravenous glucagon.
  6. 06HumanNon-randomized trialEfficacy outcome

    In normal subjects, glucagon did not affect distal esophageal contraction duration.

    In plain wordsIn normal subjects, glucagon did not change lower esophageal contraction duration compared with baseline.

    Peptide
    Glucagon
    Outcome
    No significant changeDistal contraction duration
    Study

    n = 10

    Comparator
    Baseline
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    0.25, 0.5, and 1 mg · intravenousAs given in this study (human).

    Source sentences

    Summary
    No effect on proximal amplitude of contraction and proximal or distal esophageal contraction duration was noted.
    2 context sentences
    Summary · context
    We studied 10 normal subjects to determine the effect of doses of intravenous glucagon used to treat food impaction on esophageal motor function.
    Summary · context
    With a multilumen assembly perfused by a low compliance pneumohydraulic infusion pump, esophageal manometry was performed during baseline and after randomized administration of 0. 25, 0.5, and 1 mg intravenous glucagon.
  7. 07HumanNon-randomized trialEfficacy outcome

    In normal subjects, glucagon reduced LES resting pressure from 18.7 +/- 1.8 to 10.2 +/- 1.5 mmHg (p = 0.0001).

    In plain wordsIn normal subjects, 0.25 mg glucagon reduced resting pressure in the lower esophageal sphincter compared with baseline.

    Peptide
    Glucagon
    Outcome
    DecreaseLES resting pressure after 0.25 mg
    Study

    n = 10

    Comparator
    Baseline
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    0.25 mg · intravenousAs given in this study (human).

    Measurements

    LES resting pressure (mean)
    18.7 mmHg
    baseline
    LES resting pressure spread (+/-, as reported)
    1.8 mmHg
    baseline
    LES resting pressure (mean)
    10.2 mmHg
    after 0.25 mg glucagon
    LES resting pressure spread (+/-, as reported)
    1.5 mmHg
    after 0.25 mg glucagon

    Source sentences

    Summary
    Mean LES resting pressure was significantly reduced after 0.25 mg (18.7 +/- 1.8 vs. 10.2 +/- 1.5 mmHg, p = 0.0001) and further reduced after 0.5 mg (5.9 +/- 1.2 mmHg, p = 0.0009).
    2 context sentences
    Summary · context
    We studied 10 normal subjects to determine the effect of doses of intravenous glucagon used to treat food impaction on esophageal motor function.
    Summary · context
    With a multilumen assembly perfused by a low compliance pneumohydraulic infusion pump, esophageal manometry was performed during baseline and after randomized administration of 0. 25, 0.5, and 1 mg intravenous glucagon.
  8. 08HumanNon-randomized trialEfficacy outcome

    In normal subjects, glucagon reduced LES relaxation from 93.1 +/- 2.4% to 63.6 +/- 8.8% (p = 0.0031).

    In plain wordsIn normal subjects, 0.25 mg glucagon reduced lower esophageal sphincter relaxation compared with baseline.

    Peptide
    Glucagon
    Outcome
    DecreaseLES relaxation
    Study

    n = 10

    Comparator
    Baseline
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    0.25 mg · intravenousAs given in this study (human).

    Measurements

    LES relaxation (mean)
    93.1%
    baseline
    LES relaxation spread (+/-, as reported)
    2.4%
    baseline
    LES relaxation (mean)
    63.6%
    after 0.25 mg glucagon
    LES relaxation spread (+/-, as reported)
    8.8%
    after 0.25 mg glucagon

    Source sentences

    Summary
    Mean LES relaxation was significantly reduced after 0. 25 mg (93.1 +/- 2.4% vs. 63.6 +/- 8.8%, p = 0.0031).
    2 context sentences
    Summary · context
    We studied 10 normal subjects to determine the effect of doses of intravenous glucagon used to treat food impaction on esophageal motor function.
    Summary · context
    With a multilumen assembly perfused by a low compliance pneumohydraulic infusion pump, esophageal manometry was performed during baseline and after randomized administration of 0. 25, 0.5, and 1 mg intravenous glucagon.
  9. 09HumanNon-randomized trialSafety outcome

    In normal subjects, one subject experienced transient nausea after 0.5 mg glucagon.

    In plain wordsIn normal subjects, one person had temporary nausea after 0.5 mg glucagon.

    Peptide
    Glucagon
    Outcome
    Not applicableNausea after 0.5 mg
    Study

    n = 10

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.5 mg · intravenousAs given in this study (human).

    Measurements

    Subjects with nausea
    1 subjects
    0.5 mg glucagon

    Source sentences

    Summary
    One subject experienced transient nausea after 0.5 mg, and 4 subjects experienced nausea after 1 mg glucagon.
    2 context sentences
    Summary · context
    We studied 10 normal subjects to determine the effect of doses of intravenous glucagon used to treat food impaction on esophageal motor function.
    Summary · context
    With a multilumen assembly perfused by a low compliance pneumohydraulic infusion pump, esophageal manometry was performed during baseline and after randomized administration of 0. 25, 0.5, and 1 mg intravenous glucagon.
  10. 10HumanNon-randomized trialSafety outcome

    In normal subjects, 4 subjects experienced nausea after 1 mg glucagon.

    In plain wordsIn normal subjects, 4 people had nausea after 1 mg glucagon.

    Peptide
    Glucagon
    Outcome
    Not applicableNausea after 1 mg
    Study

    n = 10

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1 mg · intravenousAs given in this study (human).

    Measurements

    Subjects with nausea
    4 subjects
    1 mg glucagon

    Source sentences

    Summary
    One subject experienced transient nausea after 0.5 mg, and 4 subjects experienced nausea after 1 mg glucagon.
    2 context sentences
    Summary · context
    We studied 10 normal subjects to determine the effect of doses of intravenous glucagon used to treat food impaction on esophageal motor function.
    Summary · context
    With a multilumen assembly perfused by a low compliance pneumohydraulic infusion pump, esophageal manometry was performed during baseline and after randomized administration of 0. 25, 0.5, and 1 mg intravenous glucagon.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.